US Stock MarketDetailed Quotes
VIRX Viracta Therapeutics
- 0.143
- -0.005-3.31%
Close Nov 29 13:00 ET
- 0.168
- +0.025+17.48%
Post 17:01 ET
5.68MMarket Cap-130P/E (TTM)
0.150High0.140Low2.07MVolume0.150Open0.148Pre Close351.15KTurnover7.20%Turnover RatioLossP/E (Static)39.74MShares1.31052wk High-0.86P/B4.11MFloat Cap0.13252wk Low--Dividend TTM28.72MShs Float9324.000Historical High--Div YieldTTM6.83%Amplitude0.132Historical Low0.169Avg Price1Lot Size
Viracta Therapeutics Stock Forum
Sign in to post a comment
This is a list in progress
NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
$Vision Marine Technologies (VMAR.US)$ News 12/1. Production Partnership for First Commercial Electric Pontoon Platform. Microfloat. C...
NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
$Vision Marine Technologies (VMAR.US)$ News 12/1. Production Partnership for First Commercial Electric Pontoon Platform. Microfloat. C...
30
12
$Viracta Therapeutics (VIRX.US)$ going to cross .35 soon
1
$Viracta Therapeutics (VIRX.US)$ did they just put out some good news and then some bad news 10 minutes later?![]()
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Viracta Therapeutics (VIRX.US)$ Should I join today
2
Viracta Therapeutics: Positive Phase 2 NAVAL-1 Trial Data, Regulatory Progress, and Future Clinical Plans.
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company, recently shared positive data from the Phase 2 NAVAL-1 trial, which focuses on relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL). This article aims to provide a comprehensive overvi...
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company, recently shared positive data from the Phase 2 NAVAL-1 trial, which focuses on relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL). This article aims to provide a comprehensive overvi...
$Viracta Therapeutics (VIRX.US)$ Viracta Therapeutics Announces Positive Data From the Phase 2 Naval-1 Trial, Regulatory Progress, and Updated Nana-Val Clinical Development Plan
2
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
105642463xu : $KULR Technology (KULR.US)$
Jaguar8 OP 105642463xu : Yup its on my watchlist
Rosscco : Thanks for the tip !
Adria87 : Thank You for the tip
baqklin : not a good play if 66% is moved to dark pool?
View more comments...